Form 4: Zimmer Biomet Director Hagemann Reports Acquisition of Phantom Stock Units and Restricted Stock Units

Director Robert Hagemann reports acquisition of phantom stock units and restricted stock units in Zimmer Biomet Holdings, Inc.

Summary

• Robert Hagemann, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 on May 14, 2024, reporting transactions that occurred on May 10, 2024.
• Hagemann acquired 616.726 phantom stock units at a price of $121.61 under the company's Deferred Compensation Plan for Non-Employee Directors.
• He also acquired 1,068.991 restricted stock units.
• The phantom stock units will be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
• Following the reported transactions, Hagemann beneficially owns 28,166.54 phantom stock units and 22,997.928 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document is a standard regulatory filing reporting insider transactions. The acquisition of stock units by a director can be seen as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of phantom stock units and restricted stock units by a director signals confidence in the company's future performance.
• The vesting and deferral terms of the restricted stock units align the director's interests with the long-term success of the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their alignment with shareholder interests.

Comparison to Industry Standards

• Stock-based compensation, including phantom stock units and restricted stock units, is a common practice among publicly traded companies to incentivize and retain key personnel, including directors.
• The vesting and deferral terms of the restricted stock units are typical for aligning director interests with long-term shareholder value.
• Companies like Johnson & Johnson (JNJ) and Stryker (SYK), which are competitors of Zimmer Biomet, also utilize similar stock-based compensation plans for their directors and executives.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the director's holdings and alignment with their interests.
• The stock-based compensation plan can incentivize the director to make decisions that benefit the company's long-term performance, which can positively impact shareholders and employees.

Key Dates